CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage.

MLA

Ziccardi, Stefano, et al. “CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage.” Neurology® Neuroimmunology & Neuroinflammation, vol. 11, no. 6, Nov. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1212/NXI.0000000000200301.

APA

Ziccardi, S., Tamanti, A., Ruggieri, C., Guandalini, M., Marastoni, D., Camera, V., Montibeller, L., Mazziotti, V., Rossi, S., Calderone, M., Pizzini, F. B., Montemezzi, S., Magliozzi, R., & Calabrese, M. (2024). CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage. Neurology® Neuroimmunology & Neuroinflammation, 11(6), 1–12. https://doi.org/10.1212/NXI.0000000000200301

Chicago

Ziccardi, Stefano, Agnese Tamanti, Claudia Ruggieri, Maddalena Guandalini, Damiano Marastoni, Valentina Camera, Luigi Montibeller, et al. 2024. “CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage.” Neurology® Neuroimmunology & Neuroinflammation 11 (6): 1–12. doi:10.1212/NXI.0000000000200301.